| Active substance |
Dapagliflozin |
| Also known as |
BMS-512148 |
| Blood pressure |
Can modestly reduce blood pressure |
| Chemical name |
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| Dosage (medical) |
Typically 10 mg once daily |
| Dosage (sports) |
Not applicable |
| Effects |
Lowers blood sugar, aids in weight loss |
| Formula |
C21H25ClO6 |
| Half-life |
Approximately 12.9 hours |
| Hepatotoxicity |
No significant hepatic toxicity reported |
| Lab Test |
Monitoring blood glucose levels and renal function tests are recommended |
| Main action |
Reduces blood glucose by inhibiting sodium-glucose transport protein 2 in the kidneys |
| Side effects |
Risk of genital infections, urinary tract infections, possible dehydration, rare cases of diabetic ketoacidosis |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Strength |
5mg |
| Substance class |
SGLT2 inhibitor |
| Trade name |
Farxiga, Xigduo XR (combination with metformin) |
| Use in sports |
Not typically used in sports |
| Water Retention |
Can cause some diuresis, generally does not cause significant water retention |
| Manufacturer |
AstraZeneca Pharma Ltd. |
| Packing |
14 tabs/blister |
